Here’s Where Topical Actives Fit
Skin tightening has become one of the busiest conversations in aesthetic medicine. Energy-based devices, injectables and mechanical procedures are all being asked to do the same job of restoring firmness to skin that has lost its structural support, whether through chronological ageing, cumulative sun exposure or the rapid changes in volume that can accompany significant weight loss as GLP-1 medication use continues to grow.
Yet energy-based treatments or a course of injections are only ever part of the aesthetic landscape. Increasingly, patients are asking practitioners what they should be doing at home to support and extend their in-clinic results. It is within this evolving landscape that FILORGA has launched its latest innovation in skin firmness, bringing the conversation around skin tightening into the patient’s at-home routine.
Why Skin Laxity Is Having a Moment
Consumer interest in skin firmness and the factors that support it has grown sharply, with FILORGA's own research citing a fivefold increase in global search interest for the term “collagen” over the past decade.¹ This interest reflects several converging trends, including an ageing population increasingly willing to seek treatment and continued advances in aesthetic medicine.² At the same time, the rise of the Pro-Aging approach reflects a broader cultural shift away from reactive correction and towards proactively supporting skin quality and natural ageing.³ More recently, significant weight loss associated with GLP-1 medications has introduced another patient group seeking support for changes in skin laxity.⁴
What Actually Happens to Collagen and Skin Structure as Laxity Develops
Skin firmness is largely determined by the integrity of the dermal extracellular matrix (ECM), where fibroblasts produce and organise collagen, elastin and hyaluronic acid to support the skin’s firmness, elasticity and hydration.⁵
With age, the balance between matrix synthesis and degradation begins to shift. Collagen content declines progressively throughout adult life, often estimated at around 1% per year, while matrix metalloproteinases (MMPs) accelerate the breakdown of existing collagen fibres.⁶ Glycation compounds this process by forming advanced glycation end-products (AGEs), which make collagen fibres stiffer and more brittle, while ageing leads to flattening of the dermo-epidermal junction (DEJ), weakening the structural connection between the epidermis and dermis.¹˒⁷
As the surrounding matrix deteriorates, fibroblasts lose some of the mechanical tension and attachment needed to function effectively, reducing their activity and new ECM production. Fibroblast numbers also decline with age, with one study reporting approximately 35% fewer fibroblasts in aged compared with younger skin.⁶ Together, these changes create a self-perpetuating cycle where less matrix is produced while more is degraded, progressively compromising skin firmness and resilience.⁶
The Signals Behind Skin Ageing
Skin ageing is driven by a combination of intrinsic factors, including chronological ageing, genetic predisposition, fibroblast senescence and hormonal changes, and extrinsic influences such as UV exposure, pollution, stress and diet.¹˒⁸ Hormonal decline is particularly relevant in women, with falling estrogen levels around menopause associated with changes in collagen content, skin thickness, hydration and elasticity.
Hormones, however, are only one part of the complex signalling network that regulates skin function. Growth factors are signalling proteins involved in processes including cell communication, tissue repair and extracellular matrix maintenance.⁹ As understanding of these pathways has evolved, growth-factor signalling has become an increasing area of interest in regenerative aesthetics.
Where Topical Actives Fit in the Aesthetic Landscape
The concept of targeting growth-factor signalling is already familiar within aesthetic medicine. Platelet-rich plasma (PRP), for example, uses a concentration of a patient’s own platelets, which release growth factors involved in cellular repair and regeneration.⁹ Peptide-based skincare approaches this biology differently. Rather than delivering the patient’s own growth factors, specific peptides can be designed to mimic or influence aspects of growth-factor signalling, targeting pathways associated with processes such as fibroblast activity and collagen synthesis.¹⁰˒¹¹
So where does this approach fit alongside established in-clinic treatments? Practitioners already have a broad range of mechanical and energy-based options at their disposal, including microneedling, ablative and non-ablative lasers, High-Intensity Focused Ultrasound (HIFU) and Microfocused Ultrasound (MFU), to name a few.¹ Topical actives sit in a different, complementary category. They cannot replicate the intensity of a controlled thermal or mechanical injury and should not be positioned as a substitute for an aesthetic procedure. Instead, their role lies in supporting skin quality through consistent, cumulative use as part of a patient’s wider treatment and skincare strategy.
Research suggests that combining complementary modalities, such as laser treatments and skincare, may produce synergistic effects, supporting both tissue healing and aesthetic outcomes.¹² For clinics, this creates several potential applications, including supporting and maintaining skin quality between in-clinic sessions, providing an accessible first step for patients who are not yet ready for a procedure and complementing treatment plans for the growing number of GLP-1 patients looking for ways to support skin quality beyond the treatment chair.
Introducing Pro-Collagen Micro-Growth Factor: The Science
At the centre of FILORGA’s new range is its Micro Growth Factor Peptides Complex, combining three peptide technologies that target complementary aspects of skin firmness. These include a micro-fragmented biomimetic FGF peptide (Palmitoyl sh-Tripeptide-1 Amide) designed to support collagen, elastin and hyaluronic acid synthesis, a biomimetic adiponectin peptide (Acetyl Tripeptide-54 Amide) targeting skin elasticity and barrier resilience and dual-matrikine messenger peptides (Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7) that support extracellular matrix renewal and skin texture.¹˒¹³˒¹⁴
Compared with larger native proteins, peptides offer several advantages for cosmetic formulation, including their smaller molecular size and potential for improved stability and skin penetration.¹˒¹⁴ In FILORGA’s ex-vivo testing, its micro-fragmented FGF peptide penetrated approximately 10 times deeper into the epidermis than the native EGF growth factor used as a comparator.¹ Importantly, despite the name, FILORGA’s Micro Growth Factor Peptides Complex does not contain growth factors themselves. Instead, its micro-fragmented FGF peptide is designed to mimic aspects of FGF signalling through a much smaller synthetic peptide.¹
What Does FILORGA Efficacy Data Show?
In ex-vivo testing submitted by FILORGA, skin explants treated with the serum formula over seven days showed a 69% increase in procollagen I, the precursor to Type I collagen, alongside a 101% increase in collagen V, which plays a role in the organisation of Type I and III collagen fibres.¹ Elastin fibre length also increased by 121%, while lumican, a protein involved in collagen fibre assembly, increased by 67% compared with untreated skin.¹ The wider evidence also supports the rationale for these peptide technologies, with growth factor-stimulating tripeptides linked to fibroblast activity and collagen deposition. A multi-ingredient serum containing two of the peptides used in FILORGA’s complex also demonstrated clinical improvements in skin firmness and elasticity over 24 weeks.¹⁵
These ex-vivo findings were accompanied by clinical improvements in a 12-week study of 36 women aged 40–60. Firmness improved by 8.2% after just seven days, reaching 20.5% after 84 days. At 12 weeks, skin smoothness had improved by 28.9% and elasticity by 17.9%.¹ These findings were reflected in the self-assessment results, with 93% of women reporting a visible improvement in skin firmness after 28 days.¹
The range launches in September 2026 as a three-step routine comprising a tightening lifting serum, lifting firming cream and lifting eye serum, each built around the same peptide complex.
The Future of Skin Firmness
As the skin-tightening category evolves, the opportunity is becoming less about choosing between topical skincare and in-clinic intervention and more about how the two can work together. While aesthetic procedures can target deeper tissue, well formulated skincare offers a way to support skin quality consistently between treatments and over the longer term.
FILORGA’s latest launch reflects this evolving approach, translating advances in peptide and growth-factor signalling research into everyday skincare. Against a backdrop of an ageing population, growing interest in proactive skin health and more patients experiencing laxity following significant weight loss, the future of skin tightening may lie not in a single treatment or ingredient, but in complementary approaches that support skin quality from the treatment room to the patient’s daily routine.
References
- Laboratoires FILORGA Cosmétiques. Pro-Collagen Micro-Growth Factor Scientific Education File (2026). [Manufacturer data on file. Supporting peer-reviewed literature is cited throughout.]
- Rashid Y, Estela-Fernandez C, Sardar A, Deowan D, Safdar OM, Issimdar IA, Camilo-Torres S, Dawood N, Ali R, Silva AB. Advances in Anti-aging Procedures: A Comprehensive Review of Surgical and Non-surgical Rejuvenation Techniques. Cureus. 2025 Sep 18;17(9):e92666. https://pmc.ncbi.nlm.nih.gov/articles/PMC12535610/
- Fabbri S, Fabbri M. Pro-Aging: A New Approach to Beauty and Aesthetic Medicine. J Cosmet Dermatol. 2025 Jun;24(6):e70277. https://pmc.ncbi.nlm.nih.gov/articles/PMC12137768/
- Haykal D, Hersant B, Cartier H, Meningaud JP. The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health. J Cosmet Dermatol. 2025 Feb;24(2):e16716. https://pmc.ncbi.nlm.nih.gov/articles/PMC11845967/
- Dong X, Xiang H, Li J, Hao A, Wang H, Gou Y, Li A, Rahaman S, Qiu Y, Li J, Mei O, Zhong J, You W, Shen G, Wu X, Li J, Shu Y, Shi LL, Zhu Y, Reid RR, He TC, Fan J. Dermal fibroblast-derived extracellular matrix (ECM) synergizes with keratinocytes in promoting re-epithelization and scarless healing of skin wounds: Towards optimized skin tissue engineering. Bioact Mater. 2025 Jan 8;47:1-17. https://pubmed.ncbi.nlm.nih.gov/39872210/
- Park S. Biochemical, structural and physical changes in aging human skin, and their relationship. Biogerontology. 2022 Jun;23(3):275-288. https://pmc.ncbi.nlm.nih.gov/articles/PMC10316705/
- Feng C, Chen X, Yin X, Jiang Y, Zhao C. Matrix Metalloproteinases on Skin Photoaging. J Cosmet Dermatol. 2024 Dec;23(12):3847-3862. https://pmc.ncbi.nlm.nih.gov/articles/PMC11626319/
- Naharro-Rodríguez J, Bacci S, Hernández-Bule ML, Pérez-González A, Fernández-Guarino M. Decoding Skin Aging: A Review of Mechanisms, Markers, and Modern Therapies. Cosmetics. 2025. https://www.mdpi.com/2079-9284/12/4/144
- Park JW, Hwang SR, Yoon IS. Advanced Growth Factor Delivery Systems in Wound Management and Skin Regeneration. Molecules. 2017 Jul 27;22(8):1259. https://pmc.ncbi.nlm.nih.gov/articles/PMC6152378/
- Cao CK, Shi ZY, Chen CB, Li XK, Su ZJ. Fibroblast Growth Factor-Derived Peptides: Sources, Functions, and Applications. Bioengineering (Basel). 2025 Sep 25;12(10):1019. https://pmc.ncbi.nlm.nih.gov/articles/PMC12561673/
- Yao C, Wu X, Wei M, Shi J. Advances in self-assembling growth factor-mimetic peptides for regenerative medicine. J Control Release. 2026;399(pt A):115334. https://www.sciencedirect.com/science/article/abs/pii/S0168365926007388
- Blyumin-Karasik M, Colon J, Nguyen S, Rosen J. Laser and Skin-Care Synergy: A Post-Laser Application of Novel Adaptogenic Moisturizing Serum for Improving Healing and Cosmesis on the Face. J Cosmet Dermatol. 2025 Feb;24(2):e16668. https://pmc.ncbi.nlm.nih.gov/articles/PMC11845916/
- Badilli U, Inal O. Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers. Polymers (Basel). 2025 Mar 18;17(6):798. https://pmc.ncbi.nlm.nih.gov/articles/PMC11946782/
- Veiga E, Ferreira L, Correia M, et al. Anti-aging peptides for advanced skincare: focus on nanodelivery systems. J Drug Deliv Sci Technol. 2023;89:105087. https://www.sciencedirect.com/science/article/pii/S1773224723009395
- Draelos ZD, Diaz I. The Benefits of a Multimechanistic Antiaging Skin Technology. Dermatol Ther (Heidelb). 2023 Dec;13(12):3111-3119. https://pubmed.ncbi.nlm.nih.gov/37861918/